Authorea (Authorea),
Journal Year:
2022,
Volume and Issue:
unknown
Published: Dec. 15, 2022
The
emerging
issue
of
rising
gabapentinoid
misuse
is
being
recognised
alongside
the
lack
current
evidence
supporting
safe
and
effective
deprescribing
gabapentinoids.
This
scoping
review
aimed
to
assess
extent
nature
interventions
in
adults,
either
reducing
dosages,
or
prescribing
of,
Electronic
databases
were
searched
on
23rd
February
2022
without
restrictions.
Eligible
studies
included
randomised,
non-randomised
observational
that
assessed
an
intervention
at
reducing/ceasing
prescription/use
a
adults
for
any
indication
clinical
setting.
research
outcomes
investigated
type
intervention,
rates,
cessations,
patient
outcomes,
adverse
events.
Extracted
outcome
data
was
categorised
as
short
(≤
3
months),
intermediate
(>3
but
<12
months)
long
(≥
12
term.
A
narrative
synthesis
conducted.
four
conducted
primary
acute
care
settings.
Intervention
dose
protocols,
education
and/or
pharmacological-based
approaches.
In
randomised
trials,
use
could
be
ceased
least
one-third
participants.
two
rates
decreased
by
9%.
Serious
events
specifically
related
gabapentinoids
reported
one
trial.
No
study
patient-focussed
psychological
process,
nor
provided
long-term
follow-up.
highlights
existing
this
area.
Due
limited
available
data,
our
unable
make
firm
judgements
most
highlighting
need
more
Pharmacy,
Journal Year:
2024,
Volume and Issue:
12(4), P. 116 - 116
Published: July 24, 2024
Non-steroidal
anti-inflammatory
drugs
(NSAIDs)
are
largely
used
for
controlling
various
pain
conditions
and
widely
available
in
community
pharmacies,
with
without
prescription.
Despite
their
effectiveness,
NSAIDs
can
pose
significant
risks
due
to
potential
side
effects
drug
interactions,
particularly
polypharmacy
comorbidity
contexts
vulnerable
users.
This
study
investigated
whether
how
deprescribing
be
conducted
at
the
pharmacy
level
by
assessing
pharmacists'
confidence,
attitudes,
barriers
facilitators.
Additionally,
we
aimed
identify
any
guidelines
that
pharmacists
could
use.
A
literature
search
a
cross-sectional
digital
questionnaire
targeting
Norway
were
conducted.
Results
showed
participants
(N
=
73)
feel
confident
identifying
needs
but
such
as
time
constraints,
lack
of
financial
compensation,
communication
challenges
noted.
Participants
reported
positive
attitudes
toward
highlighted
need
better
training.
highlights
gap
specific
enhancing
roles
process,
example,
through
training
improved
incentives.
Further
research
is
encouraged
develop
concrete
strategies
an
effective
implementation
where
involved
NSAIDs.
Trials,
Journal Year:
2022,
Volume and Issue:
23(1)
Published: April 4, 2022
Opioids
and
benzodiazepines
(BZDs)
are
some
of
the
most
commonly
prescribed
medications
that
contribute
to
falls
in
older
adults.
These
challenging
appropriately
prescribe
monitor,
with
little
guidance
on
safe
prescribing
these
for
patients.
Only
a
handful
small
studies
have
evaluated
whether
reducing
opioid
BZD
use
through
deprescribing
has
positive
impact
outcomes.
Leveraging
strengths
large
health
system,
we
targeted
consultant
pharmacist
intervention
deprescribe
opioids
BZDs
adults
seen
primary
care
practices
North
Carolina.We
developed
toolkit
process
based
literature
review
from
an
interprofessional
team
pharmacists,
geriatricians,
investigators.
A
total
fifteen
been
randomized
receive
service
(n
=
8)
or
usual
7).
The
consists
several
components:
(1)
weekly
automated
reports
identify
chronic
users
BZDs,
(2)
clinical
medication
review,
(3)
recommendations
and/or
alternate
therapies
routed
prescribers
electronic
record.
We
will
collect
data
all
patients
presenting
one
clinics
who
meet
criteria
their
prescription
order
history.
year
prior
evaluate
baseline
exposures
using
morphine
milligram
equivalents
(MMEs)
diazepam
(DMEs).
In
following
intervention,
changes
discontinuations
between
control
clinics.
Incident
be
as
secondary
outcome.
To
date,
study
enrolled
914
1048
users.
anticipate
80%
power
detect
30%
reduction
MMEs
DMEs.This
clinic
pragmatic
trial
valuable
evidence
regarding
interventions
reduce
settings.Clinicaltrials.gov
NCT04272671
.
Registered
February
17,
2020.
International Journal of Pharmacy Practice,
Journal Year:
2022,
Volume and Issue:
31(1), P. 106 - 112
Published: Nov. 10, 2022
Abstract
Objectives
Medications
and
specifically
fall-risk-increasing
drugs
(FRIDs)
are
associated
with
increased
risk
of
falls:
reducing
their
prescription
may
improve
this
risk.
This
study
explored
patient
characteristics
FRID
use,
prevalence
type
FRIDs
changes
in
prescriptions
among
older
people
arm
fractures
over
6
months.
Methods
Observational
prospective
three
fracture
clinics
England.
Patients
aged
≥65
years
a
single
upper
limb
fragility
were
recruited.
The
STOPPFall
tool
identified
the
number
prescribed
at
baseline,
3-
6-month
follow-ups.
Changes
categorised
as
discontinued,
new
or
exchanged.
Key
findings
100
patients
(median
age
73
years;
80%
female)
At
73%
used
≥1
daily
=
2),
to
64%
59%
3
months,
respectively.
Those
>1
had
significantly
higher
co-morbidities
medications
rates
male
gender,
polypharmacy,
frailty
sarcopenia.
most
frequently
antihypertensives,
opioids
antidepressants.
Between
0
44
(60%)
participants
prescription:
20
discontinued
(opioids
antihistamines),
13
started
(antidepressants)
11
exchanged
for
another.
Similar
trends
observed
Conclusion
Use
was
high.
Although
overall
use
decreased
time,
still
on
follow-up,
stop
start
Older
presenting
should
be
offered
structured
medication
review
identify
targeted
deprescribing.
British Journal of Clinical Pharmacology,
Journal Year:
2023,
Volume and Issue:
89(9), P. 2677 - 2690
Published: May 24, 2023
Abstract
The
emerging
issue
of
rising
gabapentinoid
misuse
is
being
recognized
alongside
the
lack
current
evidence
supporting
safe
and
effective
deprescribing
gabapentinoids.
This
scoping
review
aimed
to
assess
extent
nature
interventions
in
adults,
either
reducing
dosages,
or
prescribing
of,
Electronic
databases
were
searched
on
23
February
2022
without
restrictions.
Eligible
studies
included
randomized,
non‐randomized
observational
that
assessed
an
intervention
at
reducing/ceasing
prescription/use
a
adults
for
any
indication
clinical
setting.
research
outcomes
investigated
type
intervention,
rates,
cessations,
patient
adverse
events.
Extracted
outcome
data
categorized
as
short
(≤3
months),
intermediate
(>3
but
<12
months)
long
(≥12
term.
A
narrative
synthesis
was
conducted.
four
conducted
primary
acute
care
settings.
Interventions
dose‐reducing
protocols,
education
and/or
pharmacological‐based
approaches.
In
randomized
trials,
use
could
be
ceased
least
one
third
participants.
two
rates
decreased
by
9%.
Serious
events
specifically
related
gabapentinoids
reported
trial.
No
study
patient‐focused
psychological
process,
nor
provided
long‐term
follow‐up.
highlights
existing
this
area.
Due
limited
available
data,
our
unable
make
firm
judgements
most
highlighting
need
more
Frontiers in Pharmacology,
Journal Year:
2022,
Volume and Issue:
13
Published: July 18, 2022
Objectives:
Polypharmacy
and
potentially
inappropriate
medication
(PIM)
use
are
frequent
in
older
lung
cancer
patients.
This
study
aimed
to
examine
the
trends
of
polypharmacy
PIM
explore
risk
factors
for
based
on
2019
Beers
criteria
Chinese
outpatients
with
multimorbidity.
Methods:
A
repeated
cross-sectional
was
conducted
using
electronic
medical
data
consisting
prescriptions
China
from
January
2016
December
2018.
defined
as
five
or
more
medications.
The
were
used
evaluate
(age
≥65
years),
multivariate
logistic
regression
identify
use.
Results:
total
3,286
their
included
study.
prevalence
14.27%
2016,
16.55%
2017,
18.04%
use,
according
criteria,
31.94%
35.78%
42.67%
two
most
frequently
PIMs
estazolam
tramadol.
demonstrated
that
age
75
79,
polypharmacy,
irrational
drugs,
accompanied
by
sleep
disorders,
anxiety
depression,
pain
positively
associated
outpatients.
Conclusion:
multimorbidity
high
China,
increased
over
time.
Further
research
interventions
rationing
patient
population
is
needed.
Pharmacy,
Journal Year:
2022,
Volume and Issue:
10(5), P. 120 - 120
Published: Sept. 23, 2022
The
COVID-19
pandemic
has
had
a
negative
impact
on
patients'
mental
health.
aim
of
this
study
was
to
explore
whether
the
influenced
use
and
prescription
benzodiazepines
increased
need
for
community
pharmacist
involvement
in
counselling
deprescribing.
Electronic
prescription-related
data
from
one
pharmacy
Croatia
were
retrospectively
collected
period
(April
2020
March
2021)
compared
with
pre-COVID-19
2019
2020)
data.
Data
patients
diagnosed
anxiety
disorders
who
filled
out
more
than
benzodiazepines,
included
age,
sex,
number
medicines,
comorbidities.
A
total
1290
benzodiazepine
users
identified;
these,
32.87%
started
using
during
period,
while
35.2%
continued
use.
More
half
all
identified
as
potential
deprescribing
candidates
(dispensed
three
prescriptions).
Women,
older
patients,
multimorbid
individuals,
polypharmacy
likely
prolonged
period.
results
show
trend
usage
among
community-dwelling
pandemic.
Community
pharmacists
can
identify
initiate
process
that
ensures
rational
increases
safety
treatment.
Health Expectations,
Journal Year:
2023,
Volume and Issue:
27(1)
Published: Oct. 17, 2023
To
increase
our
understanding
of
which
factors
contribute
to
long-term
benzodiazepine
receptor
agonist
(BZRA)
use
for
insomnia
in
primary
care,
from
a
patients',
general
practitioners'
(GP)
and
pharmacists'
perspective.
